Review of canine hemangiosarcoma: an aggressive and lethal neoplasm
Article Sidebar
Main Article Content
Abstract
Hemangiosarcoma (HSA) is an aggressive and malignant tumor that occurs in endothelial cells and invades blood vessels. It typically occurs in canines aged 6 to 13 years, with certain breeds, including German Shepherds, Golden Retrievers, Labradors, and Boxers, are predisposed. It can occur in any part of the animal’s body and can be found in the heart, liver, skin, and bones, although its most common location is in the spleen. Its importance lies in the fact that few canines can be diagnosed before the tumor ruptures and causes severe abdominal bleeding, leading to anemia, weakness, and collapse. This study provides an updated review of various methods for diagnosis and treatment, placing emphasis on ontogeny, genetics, mutations, signaling pathways, and significant markers like CD133, CD117, CD45, and CD34. The goal is to facilitate a timely diagnosis through molecular biology and effective treatment, thereby enhancing the survival time of the canine with HSA. Likewise, the aim is to broaden the outlook for professionals at the time of early detection of HSA, to reduce the damage caused to the canine, which is extremely traumatic and painful during this pathology.
Article Details
References
Corona E, Conde A. Hemoabdomen por hemangiosarcoma en canino. Actualidades en Medicina Veterinaria y Zootecnia México (ACMEVEZ). 2020. https://acmevez.mx/hemoabdomen-por-hemangiosarcoma-en-canin/
González G. Estudio retrospectivo de las neoplasias hepáticas en caninos en el laboratorio de patología veterinaria de la Universidad Nacional de Colombia entre los años 1975 y 2007. [Tesis de posgrado]. Bogotá, Colombia: Universidad Nacional de Colombia; 2010.
Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. Journal of Veterinary Internal Medicine. 2000;14(5):479-485. doi: 10.1111/j.1939-1676.2000.tb02262.x.
Weinborn RM, Issotta CM, Agurto MK, Lara JI. Descripción clínica de hemangiosarcoma (HSA) cutáneo metastásico en un canino Galgo: estudio clínico de un caso. Revista de Medicina Veterinaria. 2015;(30):107-116. doi: 10.19052/mv.3615.
Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). Journal of the American Veterinary Medical Association. 2015;247(4):393-403. doi: 10.2460/javma.247.4.393.
Del Castillo N, del Portillo I. Revisión del hemangiosarcoma Canino. Argos: Informativo Veterinario. 2014;(155):46-50. https://www.portalveterinaria.com/animales-de-compania/articulos/24909/revision-del-hemangiosarcoma-canino.html
Yamamoto S, Hoshi K, Hirakawa A, Chimura S, Kobayashi M, Machida N. Epidemiological, clinical and pathological features of primary cardiac hemangiosarcoma in dogs: a review of 51 cases. Journal of Veterinary Medical Science. 2013;75(11):1433-1441. doi: 10.1292/jvms.13-0064.
Mantilla JD, León WA. Hemangiosarcoma en el atrio derecho estadio IV en un golden retriever macho de 8 años de edad. Reporte de caso. Repositorio Universidad de Ciencias Aplicadas y Ambientales; Colombia. 2020. https://repository.udca.edu.co/bitstream/handle/11158/3382/HSA%20ATRIAL%20GRADO%20IV%20%281%29.pdf?sequence=1&isAllowed=y
Sharun K, Basha MA, Shah MA, Kumar K, Kumar P, Shivaraju S, et al. Clinical management of cutaneous hemangiosarcoma in canines: a review of five cases. Comparative Clinical Pathology. 2019;28(6):1815-1822. doi: 10.1007/s00580-019-03039-1.
Garzón PA, Navarro GS Hemangiosarcoma dérmico de alto grado de malignidad, en un Beagle macho: Reporte de caso y presentación de caso clínico. Repositorio Universidad de Ciencias Aplicadas y Ambientales, Colombia. 2020. https://repository.udca.edu.co/bitstream/handle/11158/3606/HEMANGIOSARCOMA%20D%C3%89RMICO%20DE%20ALTO%20GRADO%20DE%20MALIGNIDAD%2C%20EN%20UN%20BEAGLE%20MACHO%2C%20REPORTE%20DE%20CASO.%20PAULA%20GARZON%20CASTILLO%2C%20GINNA%20NAVARRO.%20CIENCIAS%20AGROPRECUARIAS.%20MEDICINA%20VETERINARIA.%202020.pdf?sequence=1&isAllowed=y
García PM. Tumores cardíacos en el perro. Clínica Veterinaria de Pequeños Animales (AVEPA). 2019;39(4):207-217. https://www.clinvetpeqanim.com/img/pdf/194687501.pdf
Molina I, Cortés PM. Hemangiosarcoma atrial canino. Argos: Informativo Veterinario. 2017;(189):62-63. https://www.portalveterinaria.com/pdfjs/web/viewer.php?file=%2Fupload%2Friviste%2Fargos189.pdf
Nóbrega DF, Sehaber VF, Madureira R, Bracarense APFRL. Canine cutaneous haemangiosarcoma: biomarkers and survival. Journal of Comparative Pathology. 2019;166:87-96. doi: 10.1016/j.jcpa.2018.10.181.
Smith AN. Hemangiosarcoma in dogs and cats. Veterinary Clinics of North America: Small Animal Practice. 2003;33(3):533-52. doi: 10.1016/S0195-5616(03)00002-0.
De Nardi A, de Oliveira C, Fonseca-Alves CE, de Paiva F, Menescal LC, Carra GJ, et al. Diagnosis, prognosis, and treatment of canine hemangiosarcoma: a review based on a consensus organized by the Brazilian Association of Veterinary Oncology, ABROVET. Cancers. 2023;15(7):2025 doi: 10.3390/cancers15072025.
Gorden B, Kim JH, Sarver AL, Frantz AM, Breen M, Lindblad-Toh K, et al. Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. The American Journal of Pathology. 2014;184(4):985-995. doi: 10.1016/j.ajpath.2013.12.025.
Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GC, Modiano JF. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Experimental Hematology. 2006;34(7):870-878. doi: 10.1016/j.exphem.2006.04.013.
Carnio A, Eleni C, Cocumelli C, Bartolomé Del Pino LE, Simeoni S, Spallucci V, et al. Evaluation of intrinsic and extrinsic risk factors for dog visceral hemangiosarcoma: A retrospective case-control study register-based in Lazio region, Italy. Preventive Veterinary Medicine. 2020;181:105074. doi: 10.1016/j.prevetmed.2020.105074.
Robinson KL, Bryan ME, Atkinson ES, Keeler MR, Hahn AW, Bryan JN. Neutering is associated with developing hemangiosarcoma in dogs in the veterinary medical database: an age and time-period matched case-control study (1964-2003). Canadian Veterinary Journal, 2020;61(5):499-504. PMCID: PMC7155881.
Zwida K, Kutzler MA. 0425 Canine hemangiosarcoma expresses luteinizing hormone (LH) receptors. Journal of Animal Science. 2016;94(suppl 5):205-206. doi: 10.2527/jam2016-0425.
Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, et al. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer. 2010;10:619 doi: 10.1186/1471-2407-10-619.
Kim J-H, Frantz AM, Anderson KL, Graef AJ, Scott MC, Robinson S, et al. Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment. Experimental Cell Research. 2014;323(1):155-164. doi: 10.1016/j.yexcr.2014.02.020.
Cheng N, Schulte AJ, Santosa F, Kim JH. Machine learning application identifies novel gene signatures from transcriptomic data of spontaneous canine hemangiosarcoma. Briefings in Bioinformatics. 2021;22(4):bbaa252. doi: 10.1093/bib/bbaa252.
Montecillo CK, Aoshima K, Shibata Y, Yasui H, Yan Q, Kobayashi A, et al. KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma. Journal of Genetics and Genomics. 2021;48(7):618-630. doi: 10.1016/j.jgg.2021.02.005.
Wang G, Wu M, Maloneyhuss MA, Wojcik J, Durham AC, Mason NJ, et al. Actionable mutations in canine hemangiosarcoma. PLoS One. 2017;12(11):e0188667. doi: 10.1371/journal.pone.0188667.
Yonemaru K, Sakai H, Murakami M, Kodama A, Mori T, Yanai T, et al. The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma. The Journal of Veterinary Medical Science. 2007;69(3):271–278. doi: 10.1292/jvms.69.271.
Chen YC, Liao JW, Hsu WL, Chang SC. Identification of the two KIT isoforms and their expression status in canine hemangiosarcomas. BMC Veterinary Research. 2016;12(1):142. doi: 10.1186/s12917-016-0772-y.
Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, et al. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. Molecular Cancer Therapeutics. 2013;12(9):1701-1714. doi: 10.1158/1535-7163.MCT-12-0893.
Cletzer E, Klahn S, Dervisis N, LeRoith T. Identification of the JAK-STAT pathway in canine splenic hemangiosarcoma, thyroid carcinoma, mast cell tumor, and anal sac adenocarcinoma. Veterinary Immunology and Immunopathology. 2020;220:109996. doi: 10.1016/j.vetimm.2019.109996.
Pyuen AA, Meuten T, Rose BJ, Thamm DH. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma. PLoS ONE. 2018;13(7):e02000634. doi: 10.1371/journal.pone.0200634.
Thamm DH. Update on canine hemangiosarcoma (Proceedings). DVM 360. 2011. https://www.dvm360.com/view/update-canine-hemangiosarcoma-proceedings
Freitas J, Chieh L, Forlani G. Hemangiossarcoma canino: revisão. Pubvet. 2019;13(08):1-9. doi: 10.31533/pubvet.v13n8a389.
Wilson-Robles H, Miller T, Jarvis J, Terrell J, Kelly TK, Bygott T, et al. Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma. BMC Veterinary Research. 2021;17(1):231. doi: 10.1186/s12917-021-02934-6.
Sabattini S, Bettini G. An immunohistochemical analysis of canine haemangioma and haemangiosarcoma. Journal of Comparative Pathology. 2009;140(2-3):158-168. doi: 10.1016/j.jcpa.2008.10.006.
Kakiuchi-Kiyota S, Obert LA, Crowell DM, Xia S, Roy MD, Coskran TM, et al. Expression of hematopoietic stem and endothelial cell markers in canine hemangiosarcoma. Toxicologic Pathology. 2020;48(3):481-493. doi: 10.1177/0192623319897539.
Verge J, Albiol J, Navas M, Martín C. Angiosarcoma primario de bazo con metástasis hepáticas: presentación de un caso y revisión de la bibliografía. Cirugía Española. 2005;78(1):50-52. doi: 10.1016/S0009-739X(05)70884-8.
Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, et al. Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine. 2001;15(2):131-135. doi: 10.1111/j.1939-1676.2001.tb01244.x.
Thamm DH, Kamstock DA, Sharp CR, Jhonson SI, Mazzaferro E, Herold LV, et al. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma. Veterinary and Comparative Oncology. 2012;10(4):292-302. doi: 10.1111/j.1476-5829.2011.00298.x.
Modiano J, Helfand SC. Early detection of hemangiosarcoma and angiosarcoma. Google Patents. 2005. https://patentimages.storage.googleapis.com/78/90/fb/655669e1f37f53/US7910315.pdf
Kim JH, Graef AJ, Dickerson EB, Modiano JF. Pathobiology of hemangiosarcoma in dogs: Research advances and future perspectives. Veterinary Sciences. 2015;2(4):388-405. doi: 10.3390/vetsci2040388.
Álvarez FJ, Hosoya K, Lara A, Kisseberth W, et al. VAC protocol for treatment of dogs with stage III hemangiosarcoma. Journal of the American Animal Hospital Association. 2013;49(6):370-377. doi: 10.5326/JAAHA-MS-5954.
Sorenmo KU, Baez JL, Clifford CA, Mauldin E, Overley B, Skorupski K, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. Journal of Veterinary Internal Medicine. 2004;18(2):209-213. doi: 10.1111/j.1939-1676.2004.tb00162.x.
Ogilvie GK; Powers BE; Mallinckrodt CH; Withrow SJ. Surgery and doxorubicin in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine. 1996;10(6):379-384. doi: 10.1111/j.1939-1676.1996.tb02085.x.
Thamm DH. Canine cancer: strategies in experimental therapeutics. Frontiers in Oncology. 2019;9:1257. doi: 10.3389/fonc.2019.01257.
Bray JP, Munday JS. Thalidomide reduces vascular endothelial growth factor immunostaining in canine splenic hemangiosarcoma. Veterinary Sciences. 2020;7(2):67. doi: 10.3390/vetsci7020067.
Fukumoto S, Saida K, Sakai H, Ueno H, Iwano H, Uchide T. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma. Life Sciences. 2016.159:55-60. doi: 10.1016/j.lfs.2016.01.047.
U’Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine. 2007;21(1):113-120. doi: 10.1892/0891-6640(2007)21[113:eoantv]2.0.co;2.
Lucroy MD, Clauson RM, Suckow MA, El-Tayyeb F, Kalinauskas A.Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary stud. BMC Veterinary Research. 2020;16:447. doi: 10.1186/s12917-020-02675-y.
Konduri V, Halpert MM, Baig YC, Coronado R, Rodgers JR, Levitt JM, et al. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma. Cancer Gene Therapy. 2019;26:282-291. doi: 10.1038/s41417-019-0080-3.
Kahn SA, Mullin CM, de Lorimier LP, Burgess KE, Risbon RE, Fred RM, et al. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. Canadian Veterinary Journal. 2013;54(3):237-242. PMCID: PMC3573628.
Carlson A, Alderete KS, Grant MKO, Seelig DM, Sharkey LC, Zordoky BNM. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. Veterinary and Comparative Oncology. 2018;16(2):253-261. doi: 10.1111/vco.12375.
Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, et al. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Veterinary Research. 2015;11(1):131. doi: 10.1186/s12917-015-0446-1.
Tinsley A. Canine hemangiosarcoma: a certainly less than ideal, very ugly cancer. Preprints.org. 2020:2020080528. doi: 10.20944/preprints202008.0528.v1.
Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Laboratory Investigation. 2004;84(5):562-572. doi: 10.1038/labinvest.3700080.
Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, et al. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Research in Veterinary Science. 2006;81(1):76-86. doi: 10.1016/j.rvsc.2005.09.005.
License
Veterinaria México OA by Facultad de Medicina Veterinaria y Zootecnia - Universidad Nacional Autónoma de México is licensed under a Creative Commons Attribution 4.0 International Licence.
Based on a work at http://www.revistas.unam.mx
- All articles in Veterinaria México OA re published under the Creative Commons Attribution 4.0 Unported (CC-BY 4.0). With this license, authors retain copyright but allow any user to share, copy, distribute, transmit, adapt and make commercial use of the work, without needing to provide additional permission as long as appropriate attribution is made to the original author or source.
- By using this license, all Veterinaria México OAarticles meet or exceed all funder and institutional requirements for being considered Open Access.
- Authors cannot use copyrighted material within their article unless that material has also been made available under a similarly liberal license.